Healthcare Sector
17 articlesVisitors can use the page to follow market updates, practical investor context and market sectors, review examples and see how nearby terms changes the way a product, rule, account or market signal should be interpreted.
Merck Stock Jumps as Cancer Vaccine Data Signals New Revenue Path
Merck shares surged after a late-stage trial showed its mRNA cancer vaccine, developed with Moderna, improved outcomes for melanoma patients. Investors are watching how this could reshape Merck's future beyond Keytruda's patent window
Breakfast News: Alphabet Goes Shopping for Data
Alphabet acquires Spirit Aviation Holdings' vast trove of business data for $10 million to train AI, while Tesla eyes a driverless Cybercab launch and Meta faces a high-stakes child-safety trial with billions on the line
Hinge Health Stock Surges as Cramer Sees More Upside After Q2 Results
Hinge Health's shares have soared nearly 86% in 2026, but Jim Cramer argues the company's latest earnings and expansion moves could mean the rally is just getting started for this digital health stock
Lilly's New Weight-Loss Pill Targets Millions Avoiding Injections
Eli Lilly's once-daily pill Foundayo just won U.K. approval for obesity and diabetes, opening a market of patients who have resisted injectable drugs and intensifying competition with Novo Nordisk in a fast-growing sector
Eli Lilly's Global Obesity Drug Ambitions May Outpace U.S. Sales
Eli Lilly's latest earnings beat expectations, but Bank of America now sees the company's international obesity drug market as a bigger long-term driver than U.S. demand, raising new questions for investors
Novo Nordisk Faces Investor Pressure as Wegovy Pill Growth Shifts
Novo Nordisk is raising its 2026 outlook after a mixed quarter, but slowing stock performance and new competition are forcing the company to reset expectations for its blockbuster Wegovy pill and global expansion strategy
Portfolio Manager Shifts From Tech to Healthcare and Robotics ETFs
With tech and AI stocks dominating the S&P 500, a veteran manager is moving fresh capital into healthcare and robotics ETFs, aiming for long-term growth as sector leadership shows signs of rotation
AstraZeneca-Bristol Myers Merger Rumors Trigger Sharp Stock Split
AstraZeneca shares tumbled while Bristol Myers surged after reports of a potential $400 billion merger. Investors are weighing patent risks, pipeline strength, and regulatory hurdles as Wall Street reacts to the pharma sector's biggest deal talk in years
Morgan Stanley Warns of Sharp Downside for Bristol Myers Stock
Bristol Myers Squibb delivered strong earnings and raised its outlook, but Morgan Stanley projects a steep drop for the stock as looming patent expirations and pipeline delays cloud the company's future cash flow
Novo Nordisk Stock Drops After Heart Drug Trial Misses Key Target
Novo Nordisk shares tumbled after its heart drug Ziltivekimab failed a major late-stage trial, raising questions about the company's growth beyond weight-loss drugs and triggering a sharp market reaction
AstraZeneca Drops on Reported Bristol Myers Talks
A reported $400 billion merger would unite two drug giants at a time when AstraZeneca is still growing and Bristol Myers faces patent pressure, raising questions about strategy, antitrust risk and U.S. market access
Eli Lilly's Soaring Stock Tests the 'Own, Don't Trade' Philosophy
Eli Lilly's stock has surged nearly 400% in five years, but with shares now above $1,150, investors face a key question: does the long-term case still hold, or is it time to rethink the classic buy-and-hold approach
State Street Health Care Select Sector SPDR ETF vs. First Trust NYSE Arca Biotechnology Index Fund: A Comparison
Healthcare ETFs XLV and FBT offer sharply different approaches-one broad and low-cost, the other biotech-focused and higher risk. See how their fees, returns, volatility, and holdings stack up before choosing where to invest
UnitedHealth's Profit Jump Masks Deeper Cost Pressures for 2026
UnitedHealth Group's latest earnings beat expectations, but rising medical costs and shrinking membership signal that higher profits are coming at a price for both the company and its customers
UBS Hikes Eli Lilly Target as Prescription Data Clouds Outlook
UBS raised its price target for Eli Lilly to $1,425, outpacing other Wall Street banks, but new prescription data and high expectations ahead of earnings add risk for investors holding LLY shares into August
Biotech Stocks Outpace Tech as M&A Wave Reshapes 2026 Market
Biotech stocks are leading the market in 2026, fueled by a surge in acquisitions and a shift in regulatory policy. Investors are weighing whether the rally can continue as valuations climb and deal activity accelerates
Ionis Pharmaceuticals Stock Plunges After Consecutive Drug Setbacks
Ionis Pharmaceuticals shares tumbled nearly 29% in two days after a failed heart drug trial and a partner’s exit from Huntington’s disease programs, raising questions about future growth and competition in the biotech sector